



**SOLVE**  
**ON.**

## Incyte to Report Fourth Quarter and Year-End 2024 Financial Results

January 21, 2025

WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 21, 2025-- Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 8:00 a.m. ET on Monday, February 10, 2025.

The schedule for the press release and conference call/webcast is as follows:

- Q4 & YE 2024 Press Release: February 10, 2025 at 7:00 a.m. ET
- Q4 & YE 2024 Conference Call: February 10, 2025 at 8:00 a.m. ET
- Domestic Dial-In Number: 877-407-3042
- International Dial-In Number: 201-389-0864
- Conference ID Number: 13751174

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13751174.

The live webcast with slides can be accessed at [Investor.Incyte.com](https://investor.incyte.com) and will be available for replay for ninety days.

### About Incyte

A global biopharmaceutical company on a mission to *Solve On.*, Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit [Incyte.com](https://www.incyte.com) or follow us on social media: [LinkedIn](#), [X](#), [Instagram](#), [Facebook](#), [YouTube](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250121683622/en/): <https://www.businesswire.com/news/home/20250121683622/en/>

### Media

[media@incyte.com](mailto:media@incyte.com)

### Investors

[ir@incyte.com](mailto:ir@incyte.com)

Source: Incyte